Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26 FARMACOLOGIA GASTROENTEROLOGIA GENETICA HEALTH U.S. ONCOLOGIA RICERCA Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26 Redazione 2 Giugno 2026 Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase... Per saperne di più Maggiori informazioni su Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
